| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2021: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we tried to obtain preclinical POC for a novel treatment of colorectal cancer based on the molecular mechanism of cancer stem cells. We established a system to generate organoids derived from human clinical specimens of colorectal cancer and to quantitatively evaluate the efficacy of drugs using these organoids, as well as a system to create xenografts by transplanting these organoids into immunodeficient mice and to evaluate the efficacy of drugs against these xenografts. Using these systems, we examined the efficacy of the novel therapeutic drug candidates that the applicants had discovered in our previous studies using colon cancer cell lines, and revealed that they were effective in the systems.
|
